During the past decade, Hakodate central general hospital conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 4 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hakodate central general hospital" #1 sponsor was "Pfizer" with 4 trials, followed by "Japan Clinical Cancer Research Organization" with 3 trials sponsored, "Kyowa Kirin Co., Ltd." with 1 trials sponsored, "Nobelpharma" with 1 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hakodate central general hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Japan Blood Products Organization" with 1 trials as a collaborator, "Kitasato University" with 1 trials as a collaborator, "Korean Cancer Study Group" with 1 trials as a collaborator and "Taiho Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Hakodate central general hospital" are "Gastric Cancer" (3 trials), "Low Back Pain" (2 trials), "Acute Pain in Herpes Zoster" (1 trials), "Neuralgia" (1 trials) and "Osteoarthritis, Hip" (1 trials). Many other conditions were trialed in "Hakodate central general hospital" in a lesser frequency.

Most popular intervention types in "Hakodate central general hospital" are "Drug" (8 trials), "Biological" (3 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "S-1" (2 trials), "Antithrombin gamma" (1 trials), "Celecoxib" (1 trials) and "NPC-06" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hakodate central general hospital" are 10 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Hakodate central general hospital". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Hakodate central general hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Hakodate central general hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".